They had that in the 10K and the last 10Q. Besides what makes me think it is for real is this modification they did with Orbimed ...
"The Credit Obligors hereby agree that the Credit Obligors will obtain Lender’s written consent
prior to closing on a transaction to sell securities of Holdings to a third party other than Amgen Inc. or any employee of Holdings or Borrower during the four-month period commencing January 1, 2017 and ending April 30, 2017." -- Third Party was not defined.
Sounds to me Orbimed is expecting a deal.
I would suspect they have another "strategic partner" deal in mind as well as another investor financing deal. I believe at this point they need to put together a deal that will ensure ample funding to see them through commercialization. Hopefully this management team over the past year has earned the reputation for getting things done and managing the money well. Lets see if our CFO can earn his keep. IMO they have done a good job. (Please send all snarky comments to
[email protected])
My belief is all predicated on faith that the contracts in hand or that will be signed will ensure in the long run lenders get paid and investors see a return on their investments. If that is not the case then my see my motto at the bottom.
Also the recent stock option grants suggest perhaps, just perhaps, something is in the works. Allows the C suite to be protected against dilution and issuing them at rock bottom pricing is just a coincidence.